The vaccine that reduced the risk of infant hospitalization by 83%
Israel has implemented a new immunization schedule for infants to protect against Respiratory Syncytial Virus (RSV). Preliminary data suggests a significant reduction in hospitalizations, marking a major shift in pediatric respiratory care.
Why it matters
RSV is a leading cause of infant hospitalization; the success of this program provides a potential model for other nations to reduce the burden on pediatric healthcare systems.
For most adults and older children, contracting RSV will look like just another winter cold: runny nose, cough, and a few uncomfortable days. In an infant just a few weeks or months old, that exact same virus is liable to look completely different. Breathing becomes labored, feeding becomes difficult, oxygen levels may drop, and sometimes the path from the nursery at home ends up in the emergency room, in hospitalization, and even in intensive care.This is one of the reasons why the upcoming winter may be different for parents of infants in Israel. Following the first winter season in which protection against RSV was given to all infants in their first year of life, encouraging preliminary data is already available from Israel.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in